COST-UTILITY ANALYSIS OF APREMILAST FOR THE TREATMENT OF MODERATE TO SEVERE PSORIASIS IN SPAIN

被引：3
|
作者：
Carrascosa, J. M. [1 ]
Vanaclocha, F. [2 ]
Caloto, T. [3 ]
Echave, M. [4 ]
Oyaguez, I [4 ]
Tencer, T. [5 ]
机构：
[1] Germans Trias & Pujol Univ Hosp, Dept Dermatol, Barcelona, Spain
[2] 12 Octubre Univ Hosp, Dept Dermatol, Madrid, Spain
[3] Celgene Corp, Dept Hlth Econ, Madrid, Spain
[4] Pharmacoecon & Outcomes Res Iberia, Madrid, Spain
[5] Celgene Corp, Warren, NJ USA
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.555
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSS31
引用
收藏
页码：A420 / A420
页数：1
相关论文
共 50 条
  • [1] COST-UTILITY ANALYSIS OF APREMILAST FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN THE ITALIAN SETTING
    Barbieri, M.
    Capri, S.
    Oskar, B.
    VALUE IN HEALTH, 2015, 18 (07) : A419 - A420
  • [2] COST-UTILITY OF USTEKINUMAB IN THE TREATMENT OF MODERATE TO SEVERE PSORIASIS IN COLOMBIA
    Aguirre, A.
    Guerrero, E.
    Hernandez, N.
    Coronell, S.
    Argote, A. C.
    Giraldo, C., V
    Ojeda, C.
    VALUE IN HEALTH, 2017, 20 (05) : A211 - A211
  • [3] COST-UTILITY OF USTEKINUMAB IN THE TREATMENT OF MODERATE TO SEVERE PSORIASIS IN COLOMBIA
    Ojeda, C.
    Hernandez, N.
    Giraldo, C., V
    Argote, A. C.
    Coronell, S.
    Roa, M.
    VALUE IN HEALTH, 2016, 19 (03) : A124 - A124
  • [4] A cost-utility analysis of etanercept for the treatment of moderate-to-severe psoriasis in Italy
    Colombo, Giorgio L.
    Di Matteo, Sergio
    Peris, Ketty
    Fargnoli, Maria Concetta
    Esposito, Maria
    Mazzotta, Annamaria
    Chimenti, Sergio
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2009, 1 : 53 - 59
  • [5] A COST-UTILITY ANALYSIS OF ETANERCEPT FOR THE TREATMENT OF MODERATE-TO-SEVERE PSORIASIS IN ITALY
    Di Matteo, S.
    Colombo, G. L.
    VALUE IN HEALTH, 2009, 12 (07) : A457 - A457
  • [6] COST-UTILITY ANALYSIS OF APREMILAST FOR THE TREATMENT OF PSORIATIC ARTHRITIS PATIENTS IN SPAIN
    Gonzalez, C. M.
    Almodovar, R.
    Caloto, T.
    Echave, M.
    Elias, T.
    Tencer, T.
    VALUE IN HEALTH, 2015, 18 (07) : A645 - A645
  • [7] Cost-utility analysis of Amevive™ (alefacept) in the treatment of patients with moderate-to-severe psoriasis
    Iskedjian, M
    Barkovsky, L
    Desjardins, O
    Walker, JH
    Dorkalam, M
    Shear, N
    Einarson, TR
    VALUE IN HEALTH, 2005, 8 (03) : 331 - 331
  • [8] Cost-utility and budget impact analysis of adding-on apremilast to biologic therapy in the treatment of moderate to severe plaque psoriasis, an Iranian payer perspective
    Zargaran, Marzieh
    Soleymani, Fatemeh
    Nasrollahi, Saman Ahmad
    Seyedifar, Meysam
    Rahaghi, Mohammad Mehdi Ashrafian
    RESEARCH IN PHARMACEUTICAL SCIENCES, 2021, 16 (04) : 381 - 390
  • [9] BUDGET IMPACT ANALYSIS OF APREMILAST ON MODERATE TO SEVERE PSORIASIS IN SPAIN
    Vanaclocha, F.
    Carrascosa, J. M.
    Caloto, T.
    Elias, I
    Echave, M.
    Tencer, T.
    VALUE IN HEALTH, 2015, 18 (07) : A421 - A421
  • [10] COST-UTILITY ANALYSIS OF ADALIMUMAB FOR THE TREATMENT OF MODERATE-TO-SEVERE ULCERATIVE COLITIS IN PATIENTS IN SPAIN
    Wang, S.
    Yang, H.
    Yang, M.
    Bao, Y.
    VALUE IN HEALTH, 2015, 18 (07) : A670 - A670
12345